Instituto de Investigación Biomédica de A Coruña (INIBIC)
Centro de investigación
Hospital Sagrado Corazón
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Hospital Sagrado Corazón (15)
2021
-
BRCA1 Expression and Outcome in Patients With EGFR-Mutant NSCLC Treated With Gefitinib Alone or in Combination With Olaparib
JTO Clinical and Research Reports, Vol. 2, Núm. 3
-
Incidence, diagnosis, and outcome of immune-mediated thrombotic thrombocytopenic purpura: A nationwide survey by the Spanish registry of thrombotic thrombocytopenic purpura
Journal of Clinical Apheresis, Vol. 36, Núm. 4, pp. 563-573
-
The SEEN comprehensive clinical survey of adult obesity: Executive summary
Endocrinologia, Diabetes y Nutricion, Vol. 68, Núm. 2, pp. 130-136
2019
-
Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer
Journal of Thoracic Oncology, Vol. 14, Núm. 2, pp. 304-310
-
BRAF mutations classes I, II, and III in NSCLC patients included in the SLLIP trial: The need for a new pre-clinical treatment rationale
Cancers, Vol. 11, Núm. 9
-
EGFR first- and second-generation TKIs-there is still place for them in EGFR-mutant NSCLC patients
Translational Cancer Research, Vol. 8, pp. S23-S47
-
Integrin-linked kinase (ILK) and src homology 2 domain-containing phosphatase 2 (SHP2): Novel targets in EGFR-mutation positive non-small cell lung cancer (NSCLC)
EBioMedicine, Vol. 39, pp. 207-214
-
PIM-1 inhibition with AZD1208 to prevent osimertinib-induced resistance in EGFR-mutation positive non-small cell lung cancer
Journal of Cancer Metastasis and Treatment, Vol. 5
2018
-
Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC
Translational Lung Cancer Research, Vol. 7, Núm. 6, pp. 691-702
-
Strategies for first-line immunotherapy in squamous cell lung cancer: Are combinations a game changer?
Translational Lung Cancer Research, Vol. 7, pp. S198-S201
2017
-
GRECOS Project (Genotyping Recurrence Risk of Stroke): The Use of Genetics to Predict the Vascular Recurrence after Stroke
Stroke, Vol. 48, Núm. 5, pp. 1147-1153
2014
2013
2011
-
Clinical characteristics and disease course in patients treated with efalizumab following suspension of marketing authorization by the European Medicines Agency: A multicenter observational study
Actas Dermo-Sifiliograficas, Vol. 102, Núm. 5, pp. 354-364
2002
-
Heterozygous familial hypercholesterolemia in Spain. Description of 819 non related cases
Medicina Clinica, Vol. 118, Núm. 13, pp. 487-492